Boston Scientific Corporation BSX
Strong Medical Devices & Diagnostics sector · Boston Scientific — diversified medical devices (cardiology, electrophysiology) compounding above-market.
Boston Scientific Corporation (BSX) is an established Medical Devices & Diagnostics company, graded Strong on FrontierLab's evidence-based quality rubric (data as of 2026-08-21). Revenue grew 13.5% year-over-year at a 71.2% gross margin. Gross-profits-to-assets is 0.33; Rule of 40 is 35. Net share issuance -0.6% YoY (flat share count). 1 risk flag is noted below. Analyst mix: 30 buy / 8 hold / 0 sell. 3 distinct insider cluster-buyers in the last 90 days.
These sentences are generated from the day's data by deterministic templates.
Key quality signals
| Revenue growth (YoY) | 13.5% |
|---|---|
| Gross margin | 71.2% |
| Gross profits / assets | 0.33 |
| Rule of 40 | 35 |
| Net margin | 21.5% |
| Cash runway (months) | — |
| PEG | 0.4 |
| Price / sales | 3.5 |
Quality checklist
Each line is one quality test behind the grade — ✓ passed · ~ borderline · ✗ failed. Hover a metric in the tables below for what it means.
- ~ Revenue growth — 13.5% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.33 (pass ≥ 0.33)
- · Rule of 40 — 35 (context — graded for software only)
- ✓ Gross margin — 71.2% (pass ≥ 60% · Medical Devices & Diagnostics)
- ✓ Cash generation
- ✓ Share dilution — -0.6%
- ~ Competitive moat — Narrow
- ✓ Market size (TAM) — Large
Grade history
Graded Strong since 2026-06-17 — no grade changes recorded yet.
How have Strong-graded names performed?
The forward returns of all Strong-graded names since each grade was recorded — the bucket this name currently sits in, not a forecast of this individual stock.
| Window | Forward record vs the S&P | Median |
|---|---|---|
| ~1 month | 59% of Strong-graded names beat the S&P over 21 sessions (95% CI 41–74%, N=29). | Median excess vs the S&P was +4.2%. |
| ~3 months | building — 13 more sessions needed | |
| ~6 months | building — 76 more sessions needed | |
How have this name's flags scored?
| Flag | N | Mean excess vs S&P |
|---|---|---|
| News: management cut guidance. | sample still too small to report (need ≥ 8) | |
These per-flag figures are observational — a flag firing is not a randomized assignment, so any edge can reflect what kind of names trip a flag, not the flag itself. Descriptive, not causal.
Scope: these are forward returns vs the S&P among names still covered at each horizon's end, within the curated universe — not a survivorship-clean whole-market backtest. Names later dropped from coverage are counted as attrition (not hidden), and single-session moves beyond ±300% are treated as split/data artifacts and excluded. How this is measured → · Full track record →
How it compares
Coarse same-sector, same-stage context — not a percentile or rank. GP/A is graded on its absolute level, not position.
Fundamentals
| Market cap | $73.38B |
|---|---|
| Stage | Established |
| Share issuance (YoY) | -0.6% · flat share count |
| Moat | Narrow |
| TAM | LARGE |
| P/E (trailing) | 20.1 |
| EPS (trailing) | $2.46 |
| Burn multiple | — |
| Gross-margin trend (pts) | 8 |
| Cash / assets | 0.01 |
| Accruals (%) | -2% |
| Net debt / EBITDA | 2.1 |
| Statements as of | Q2 FY2026 · filed 2026-08-03 |
Momentum context — describes the past, not a signal
Low reached Jul 14, 2026 · high reached Sep 8, 2025 — by daily close.
| Price | $49.37 (as of 2026-08-20) |
|---|---|
| Last session move | — |
| % off 52-wk high | -54.9% |
| RSI (14) | 53 |
| Relative volume | 1× |
Risk flags
Positive signals
Insider activity (90 days)
| Cluster buyers | 3 |
|---|---|
| Sellers | 0 |
Insider selling is routine diversification, not a bearish signal.
Analyst mix
| Strong buy | 11 |
|---|---|
| Buy | 19 |
| Hold | 8 |
| Sell | 0 |
| Strong sell | 0 |
▼ Analyst view softening — net -1 buy rating, coverage 39→38 analysts over ~4 weeks (per aggregated analyst ratings)
Ratings are context, not a price target. "Momentum" = how the mix changed over recent weeks, not a forecast.
From the headlines
Lower 2026 growth guidance raises questions about buyback timing.
- If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today
- Boston Scientific (BSX), What Is Behind The Latest Investor Attention?
- Is Boston Scientific’s (BSX) Buyback at Odds with Its Lower 2026 Growth Guidance?
AI take — daily, AI-generated
AI leans positive
Stellar fundamentals with a 0.4 PEG and 71% margins, but lowered 2026 guidance signals caution; the 100% bullish sentiment feels disconnected from that headwind.
Generated by an AI model from the day's news — an opinion for context only. Not financial advice, not a recommendation, and not a price target.
Similar Medical Devices & Diagnostics names
← All Medical Devices & Diagnostics names · Open BSX in the interactive screener →
Data as of 2026-08-21 08:12 (end-of-day). How grades are computed →